Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic...
share announcement

Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 1740

Special Issue Editors

Dr. Brian S Finkelman

E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Interests: cancer biomarkers; HER2; endometrial cancer; breast cancer; gynecologic cancer; prediction modeling; prognostic risk-stratification
Dr. Rachelle P Mendoza

E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Interests: gynecology; cytology; pathology; oncology; placenta
Dr. Hani Katerji

E-Mail Website
Guest Editor
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
Interests: breast cancer; gynecologic cancer; prognostic and predictive breast and gynecologic cancer biomarkers

Special Issue Information

Dear Colleagues,

Biomarkers play an essential role in the early detection, prognosis, and prediction of treatment response in cancer. Biomarkers are based on qualitative and/or quantitative assessment of biomolecules, such as DNA, RNA, and proteins. Biomarker detection can be performed on a variety of tissue samples, including tumor tissue derived from biopsies or surgical specimens, as well as less invasive samples such as blood, cervical Pap smears, and vaginal secretions, among others. 

In gynecologic cancers—including cancers of the uterine corpus, uterine cervix, fallopian tube, ovary, vagina, and vulva—biomarkers have increased in clinical relevance in recent years. For instance, molecular testing for high-risk subtypes of human papilloma virus (HPV) has transformed cervical cancer screening, while testing for HER2 expression has recently increased therapy options for some patients with endometrial serous carcinoma.

This Special Issue of Cancers encompasses new research articles and up-to-date reviews on all aspects of biomarkers and their relationship to treatment prediction, prognosis, and early detection of gynecologic cancer. Special attention will be given to submissions with clinical relevance.

Dr. Brian S Finkelman
Dr. Rachelle P Mendoza
Dr. Hani Katerji
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • endometrial cancer
  • uterine cancer
  • cervical cancer
  • ovarian cancer
  • vulvar cancer
  • treatment prediction
  • prognosis
  • early detection

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1517 KiB  
Article
Expression of Potential Antibody–Drug Conjugate Targets in Cervical Cancer
by Michael R. Mallmann, Sina Tamir, Katharina Alfter, Dominik Ratiu, Alexander Quaas and Christian M. Domroese
Cancers 2024, 16(9), 1787; https://doi.org/10.3390/cancers16091787 - 6 May 2024
Viewed by 631
Abstract
(1) Background: There is a huge unmet clinical need for novel treatment strategies in advanced and recurrent cervical cancer. Several cell membrane-bound molecules are up-regulated in cancer cells as compared to normal tissue and have revived interest with the introduction of antibody–drug conjugates [...] Read more.
(1) Background: There is a huge unmet clinical need for novel treatment strategies in advanced and recurrent cervical cancer. Several cell membrane-bound molecules are up-regulated in cancer cells as compared to normal tissue and have revived interest with the introduction of antibody–drug conjugates (ADCs). (2) Methods: In this study, we characterize the expression of 10 potential ADC targets, TROP2, mesotheline, CEACAM5, DLL3, folate receptor alpha, guanylatcyclase, glycoprotein NMB, CD56, CD70 and CD138, on the gene expression level. Of these, the three ADC targets TROP2, CEACAM5 and CD138 were further analyzed on the protein level. (3) Results: TROP2 shows expression in 98.5% (66/67) of cervical cancer samples. CEACAM5 shows a stable gene expression profile and overall, 68.7% (46/67) of cervical cancer samples are CEACAM-positive with 34.3% (23/67) of cervical cancer samples showing at least moderate or high expression. Overall, 73.1% (49/67) of cervical cancer samples are CD138-positive with 38.8% (26/67) of cervical cancer samples showing at least moderate or high expression. (4) Conclusions: TROP2, CEACAM5 or CD138 do seem suitable for further clinical research and the data presented here might be used to guide further clinical trials with ADCs in advanced and recurrent cervical cancer patients. Full article
(This article belongs to the Special Issue Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic Cancer)
►▼ Show Figures

Figure 1

22 pages, 2705 KiB  
Article
Circulating Adipocytokines and Insulin Like-Growth Factors and Their Modulation in Obesity-Associated Endometrial Cancer
by Irene Ray, Carla S. Möller-Levet, Agnieszka Michael, Simon Butler-Manuel, Jayanta Chatterjee, Anil Tailor, Patricia E. Ellis and Lisiane B. Meira
Cancers 2024, 16(3), 531; https://doi.org/10.3390/cancers16030531 - 26 Jan 2024
Viewed by 924
Abstract
The rising global incidence of uterine cancer is linked to the escalating prevalence of obesity. Obesity results in alterations in adipocytokines and IGFs, driving cancer progression via inflammation, increased cell proliferation, and apoptosis inhibition, although the precise mechanisms are still unclear. This study [...] Read more.
The rising global incidence of uterine cancer is linked to the escalating prevalence of obesity. Obesity results in alterations in adipocytokines and IGFs, driving cancer progression via inflammation, increased cell proliferation, and apoptosis inhibition, although the precise mechanisms are still unclear. This study examined a set of six markers, namely, adiponectin, leptin, IL6, TNFα, IGF1, and IGF2 and compared them between fifty age-matched endometrial cancer patients (study group) and non-cancer patients with benign gynaecological conditions (control group). We also assessed the relationship of these markers with obesity and explored the correlation between these markers and various tumour characteristics. In the cancer population, these markers were also assessed 24 h and 6 months post-surgery. Remarkably, low adiponectin levels were associated with a 35.8% increase in endometrial cancer risk. Interestingly, compared to control subjects where IGF levels decreased after menopause, post-menopausal women in the study group showed elevated IGF1 and IGF2 levels, suggesting a potential influence of endometrial cancer on the IGF system, particularly after menopause. Lastly, it is noteworthy that a discernible inverse relationship trend was observed in the levels of adipocytokines and IGFs 6 months post-surgery. This indicates that treatment for endometrial cancer may have a differential impact on adipocytokines and IGFs, potentially holding clinical significance that merits further investigation. Full article
(This article belongs to the Special Issue Biomarkers for Treatment Prediction, Prognosis and Early Detection of Gynecologic Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop